Maxime Verhoeven

56 Chapter 3 Supplementary Figure S1a Percentage (SE) of patients achieving DAS28 remission for each strategy arm as predicted by model. Supplementary Figure S1b Percentage (SE) of patients achieving modified CDAI re- mission in each strategy arm as predicted by model. DAS28= disease activity score assessing 28 joints; SE= standard error; MTX (ref)= methotrexate + placebo strategy used as reference arm in the analysis; MTX+Pred= methotrexate + prednisone strategy arm; TCZ+MTX= tocilizumab + methotrexate strategy arm; TCZ= tocilizumab + placebo strategy arm, M-CDAI= modified CDAI. Supplementary Figure S2 Mean (SE) HAQ scores over time for each strategy arm as predicted by model. HAQ= health assessment questionnaire; SE= standard error; MTX (ref)= methotrexate + placebo strategy used as reference arm in the analysis; MTX+Pred= methotrexate + prednisone strategy arm; TCZ+MTX= tocilizumab + methotrexate strategy arm; TCZ= tocilizumab + placebo strategy arm.